Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relative age effect

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    642 result(s) found for: Relative age effect. Displaying page 9 of 33.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2005-000365-19 Sponsor Protocol Number: CFTY720D2301 Start Date*: 2005-12-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo ...
    Medical condition: Relapsing-remitting multiple sclerosis (RRMS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) CZ (Completed) DE (Completed) SK (Completed) FI (Completed) HU (Completed) GR (Completed) IE (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001004-37 Sponsor Protocol Number: CRTH258B2305 Start Date*: 2019-07-26
    Sponsor Name:Novartis Pharma AG
    Full Title: A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab every 4 weeks versus Aflibercept every 4 weeks in Adult Patients with Vis...
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-001442-29 Sponsor Protocol Number: D3461C00007 Start Date*: 2016-01-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003076-14 Sponsor Protocol Number: ANT-007 Start Date*: 2022-05-10
    Sponsor Name:Anthos Therapeutics
    Full Title: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in ...
    Medical condition: venous thromboembolism (VTE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003085-12 Sponsor Protocol Number: ANT-008 Start Date*: 2022-05-10
    Sponsor Name:Anthos Therapeutics
    Full Title: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding i...
    Medical condition: venous thromboembolism (VTE) in patients with gastrointestinal/genitourinary cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001320-34 Sponsor Protocol Number: 2020-6384 Start Date*: 2020-04-10
    Sponsor Name:Radboudumc
    Full Title: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease
    Medical condition: SARS-CoV-2 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000384-23 Sponsor Protocol Number: 1434-0004 Start Date*: 2022-06-15
    Sponsor Name:Boehringer Ingelheim SComm
    Full Title: A multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics profile of BI 764198 administe...
    Medical condition: Glomerulosclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) IE (Completed) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001507-35 Sponsor Protocol Number: AZA PH GL 2003 CL 001 Start Date*: 2005-03-07
    Sponsor Name:Pharmion Corporation
    Full Title: A Multicenter, Randomized, Open-Label, Parallel-Group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatm...
    Medical condition: The myelodysplastic syndromes (MDS) are a group of potentially acute myeloid leukemic disorders. The disorders of myeloid origin include acute myeloid leukemia (AML), MDS and myeloproliferative dis...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10028533 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2022-000578-25 Sponsor Protocol Number: GS-US-626-6216 Start Date*: 2023-01-12
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients Wi...
    Medical condition: Metastatic Non–Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001446-24 Sponsor Protocol Number: 178-CL-201 Start Date*: 2014-10-09
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 1, Single Dose, 4-Period Crossover Study to Assess the Bioavailability of an Mirabegron Oral Suspension Relative to the Mirabegron Prolonged Release Tablet and to Assess the Effect of Food ...
    Medical condition: No medical indication will be investigated as only healthy subjects will be included.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000243-80 Sponsor Protocol Number: MSV_LE Start Date*: 2022-05-26
    Sponsor Name:Hospital Universitario Rio Hortega
    Full Title: PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF MESENCHYMAL CELLS (MSV-allo®) IN THE TREATMENT OF LUPUS NEPHRITIS.
    Medical condition: Lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002475-29 Sponsor Protocol Number: GS-US-218-1502 Start Date*: 2015-02-10
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT...
    Medical condition: Respiratory Syncytial Virus (RSV) Infection of the lower respiratory tract.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10039247 RSV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004837-34 Sponsor Protocol Number: CAEB1102-300A Start Date*: 2019-06-18
    Sponsor Name:Aeglea Biotherapeutics, Inc.
    Full Title: PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and ...
    Medical condition: Arginase 1 Deficiency Hyperargininemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10062695 Arginase deficiency PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002931-25 Sponsor Protocol Number: VP-VLY-686-2101 Start Date*: 2013-11-05
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT, ANTIPRURITIC STUDY OF THE NEUROKININ-1 RECEPTOR ANTAGONIST VLY-686 IN SUBJECTS WITH TREATMENT-RESISTANT PRURITUS ASSOCIATED WITH AT...
    Medical condition: Males or females with treatment resistant pruritus associated with atopic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006249-42 Sponsor Protocol Number: D5252C00008 Start Date*: 2008-02-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, randomised, open-label, cross-over study to compare HFA vs CFC pMDI formulations of budesonide on methacholine hyper-reactivity in patients with stable, persistent, mild to moderate asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000498-19 Sponsor Protocol Number: GA30067 Start Date*: 2016-10-13
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA29350 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHR...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2022-001585-36 Sponsor Protocol Number: AMC_SMILE_1.0 Start Date*: 2022-07-05
    Sponsor Name:Amsterdam UMC
    Full Title: EffectS of L-glutaMIne on oxIdative stress, sickLE erythrocyte viability, inflammation and endothelial activity in sickle cell disease (SMILE trial)
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000239-28 Sponsor Protocol Number: D1693C00001 Start Date*: 2013-07-15
    Sponsor Name:AstraZeneca AB
    Full Title: DECLARE Dapagliflozin Effect on CardiovascuLAR Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence o...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    19.1 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) IT (Completed) SE (Completed) SK (Completed) BG (Completed) NL (Completed) ES (Completed) DE (Completed) PL (Completed) HU (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006070-73 Sponsor Protocol Number: D4300C00033 Start Date*: 2012-08-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid ...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-003558-26 Sponsor Protocol Number: ABX464-103 Start Date*: 2019-12-10
    Sponsor Name:ABIVAX
    Full Title: A randomized, double blind, placebo controlled, parallel group, multiple dose, induction study to evaluate the safety, tolerability and optimal dose of ABX464 compared with placebo in patients with...
    Medical condition: Moderate to Severe Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SI (Completed) CZ (Completed) DE (Completed) SK (Completed) HU (Completed) PL (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 11 17:12:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA